Merck Serono has expanded its oncology activities into antibody drug conjugates (ADCs) through a deal signed with Cambridge, Massachusetts-based Mersana Therapeutics.
The companies will research the use of Mersana's Fleximer technology to attach a range of cytotoxic agents to monoclonal antibodies...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

